School of Medicine and Health Sciences Poster Presentations

Title

Impact of Smoking Status on Remission in Hidradenitis Suppurativa

Document Type

Poster

Abstract Category

Health Sciences

Keywords

Smoking, Hidradenitis suppurativa

Publication Date

Spring 5-1-2019

Abstract

Hidradenitis suppurativa (HS) affects approximately 1-4% of the population. HS is a chronic, recurrent, inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The disease has several known risk factors, one of which is smoking. HS severity is correlated with smoking. However, until now no studies have investigated the impact of smoking on remission rates with therapeutic interventions including surgery and biologic therapy. The purpose of this study is to identify the correlation of smoking status on HS disease activity. This study was conducted through the Wound Etiology and Healing Study (WE-HEAL Study), a biospecimen and data repository approved by The George Washington University IRB (041408). All subjects gave written informed consent for longitudinal collection of their data while they receive treatment according to standard of care. Demographic data, baseline medical comorbidities, smoking exposure and disease activity scores were abstracted from the electronic health record (EHR) and stored using REDCap in the WE-HEAL study database. At datalock, there were 132 patients observed in the HS cohort. Patients were subdivided into groups based upon smoking status: smoker, non-smoker, former smoker (smoking cessation occurred prior to baseline visit), and quit smoking (smoking cessation occurred after baseline visit). Disease activity was assessed using Hurley Stage and Hidradenitis Sartorius Score (HSS). Remission rates were evaluated using the Hidradenitis Suppurativa Clinical Response (HiSCR).

Open Access

1

Comments

Presented at Research Days 2019.

This document is currently not available here.

Share

COinS
 

Impact of Smoking Status on Remission in Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) affects approximately 1-4% of the population. HS is a chronic, recurrent, inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The disease has several known risk factors, one of which is smoking. HS severity is correlated with smoking. However, until now no studies have investigated the impact of smoking on remission rates with therapeutic interventions including surgery and biologic therapy. The purpose of this study is to identify the correlation of smoking status on HS disease activity. This study was conducted through the Wound Etiology and Healing Study (WE-HEAL Study), a biospecimen and data repository approved by The George Washington University IRB (041408). All subjects gave written informed consent for longitudinal collection of their data while they receive treatment according to standard of care. Demographic data, baseline medical comorbidities, smoking exposure and disease activity scores were abstracted from the electronic health record (EHR) and stored using REDCap in the WE-HEAL study database. At datalock, there were 132 patients observed in the HS cohort. Patients were subdivided into groups based upon smoking status: smoker, non-smoker, former smoker (smoking cessation occurred prior to baseline visit), and quit smoking (smoking cessation occurred after baseline visit). Disease activity was assessed using Hurley Stage and Hidradenitis Sartorius Score (HSS). Remission rates were evaluated using the Hidradenitis Suppurativa Clinical Response (HiSCR).